- Trial Phase
- Phase 1 complete; Phase 2-ready (no Phase 2 enrollment started as of latest filings)
- Time to Market
- Several years out — Phase 2 has not begun, no registrational trial is enrolled, and FDA requires additional CMC work (in vivo relative bioavailability study for the capsule-to-tablet switch) before confirmatory trials; realistic approval is 4+ years away if development goes well.
- Why 4/10
- No hard, dated catalyst for NEO212 in the next ~12 months: Phase 1 is complete (RP2D 610 mg), but Phase 2 has not started, the FDA Type B End-of-Phase 1 meeting was canceled in favor of written CMC feedback (July 15, 2026 8-K), and the company has only promised an undated "updated development plan" — the August 2026 Phase 2a data catalyst belongs to the sibling drug NEO100, not NEO212, so impactScore stays at the default 4.
Watch for NeOnc's updated NEO212 development plan (timelines/costs for the FDA-required in vivo bioavailability study and capsule-to-tablet CMC work) and any announcement of the UAE Phase 2 start — those are the next NEO212-specific value events, but none is dated. Separately, the Aug 12 Phase 2a topline for the OTHER drug NEO100 (48.9% PFS-6 vs 20% benchmark) is what has been moving NTHI recently, so do not conflate the two programs. Note the tight balance sheet: per Q1 2026 reporting, funding runs only into September 2026, and an effective S-3 shelf plus a resale prospectus signal dilution overhang.
Price Chart
Executive Summary
NEO212 is NeOnc Technologies' oral temozolomide-perillyl alcohol conjugate for aggressive brain tumors, one of two lead programs (alongside intranasal NEO100) at this ~$113M market-cap, pre-revenue Nasdaq biotech (NTHI). Phase 1 is complete with a 610 mg recommended Phase 2 dose; NEO212 has FDA CMC alignment in progress (constructive written feedback in July 2026) and a first international IND clearance from Abu Dhabi, but no Phase 2 enrollment or dated readout yet. The stock's recent August 2026 catalysts — the Phase 2a topline (48.9% six-month PFS vs 20% benchmark) and insider buying — center on the separate NEO100 program and the CEO's open-market purchases, respectively.
How It Works
NEO212 is one pill that chemically fuses two molecules: temozolomide, the standard chemotherapy that kills cancer cells by damaging their DNA, and perillyl alcohol, a plant-derived compound that can cross the blood-brain barrier and is thought to help the drug reach brain tumors. The idea is a brain-penetrant, oral chemotherapy for aggressive brain cancers like glioblastoma, potentially more effective than giving temozolomide alone.
Trial Status
Phase 1 dose escalation completed and established 610 mg as the recommended Phase 2 dose. Department of Health – Abu Dhabi granted NEO212 IND status (June 18, 2026 8-K), the first international clearance, opening a UAE Phase 2 pathway alongside U.S. FDA talks on a potential registrational path. On July 15, 2026, FDA provided written CMC feedback deeming the proposed approach "reasonable" but requiring an in vivo relative bioavailability study plus additional formulation/GMP work before a tablet can be used in confirmatory trials; the company canceled the Type B End-of-Phase 1 meeting and said it will issue an updated development plan.
The Two-Sided Case
Upcoming Catalysts
- Undated: NeOnc's updated NEO212 development plan (timeline/cost for bioavailability study, capsule-to-tablet CMC, Phase 2 design) — the key NEO212-specific event to watch
- Potential UAE Phase 2 initiation following DOH Abu Dhabi IND clearance (no date announced)
- Company-level: Q2 2026 earnings per events calendar listed Aug 25, 2026; ongoing FDA discussions for NEO100's registrational path after its Aug 12 Phase 2a topline (sibling program, not NEO212)
Source Filing
The SecBot filing or press-release report that triggered this drug report:
NEONC TECHNOLOGIES HOLDINGS, INC. 8-K NTHI ·Originating report